| Literature DB >> 32722638 |
Laura Templier1,2, Cecilia Rossi1,2, Manuel Miguez3, Javier De la Cruz Pérez1, Adrián Curto2, Alberto Albaladejo2, Manuel Lagravère Vich4.
Abstract
Obstructive sleep apnea (OSA) is a sleeping breathing disorder. In children, adenotonsillar hypertrophy remains the main anatomical risk factor of OSA. The aim of this study was to assess the current scientific data and to systematically summarize the evidence for the efficiency of adenotonsillectomy (AT) and orthodontic treatment (i.e., rapid maxillary expansion (RME) and mandibular advancement (MA)) in the treatment of pediatric OSA. A literature search was conducted in several databases, including PubMed, Embase, Medline, Cochrane and LILACS up to 5th April 2020. The initial search yielded 509 articles, with 10 articles being identified as eligible after screening. AT and orthodontic treatment were more effective together than separately to cure OSA in pediatric patients. There was a greater decrease in apnea hypoapnea index (AHI) and respiratory disturbance index (RDI), and a major increase in the lowest oxygen saturation and the oxygen desaturation index (ODI) after undergoing both treatments. Nevertheless, the reappearance of OSA could occur several years after reporting adequate treatment. In order to avoid recurrence, myofunctional therapy (MT) could be recommended as a follow-up. However, further studies with good clinical evidence are required to confirm this finding.Entities:
Keywords: apnea; orthodontic treatments; surgical
Year: 2020 PMID: 32722638 PMCID: PMC7463535 DOI: 10.3390/jcm9082387
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Search strategy.
| MedLine (N = 129) (Ovid) | Database: Ovid MEDLINE(R) ALL <1946 to 1 April 2020> | |||
| Search Strategy: | ||||
| -------------------------------------------------------------------------------- | ||||
| 1) apnea.mp. or exp Apnea/ | 55,675 | |||
| 2) expansion.mp. | 167,509 | |||
| 3) extraction.mp. | 275,062 | |||
| 4) orthodon *.mp. | 57,238 | |||
| 5) 2 or 3 or 4 | 491,026 | |||
| 6) tonsil *.mp. | 36,364 | |||
| 7) adenoid *.mp. | 17,236 | |||
| 8) 6 or 7 | 47,732 | |||
| 9) 1 and 5 and 8 | 129 | |||
| Embase (N = 194) (Ovid) | Database: Embase <1974 to 1 April 2020> | |||
| Search Strategy: | ||||
| -------------------------------------------------------------------------------- | ||||
| 1) exp apnea/or apnea.mp. | 92,729 | |||
| 2) expansion.mp. | 215,648 | |||
| 3) exp extraction/or extraction.mp. | 443,345 | |||
| 4) orthodon *.mp. | 54,485 | |||
| 5) 2 or 3 or 4 (704,171) | 704,171 | |||
| 6) tonsil *.mp. (42,139) | −42,139 | |||
| 7) adenoid *.mp. | 18,653 | |||
| 8) 6 or 7 | 55,708 | |||
| 9) 1 and 5 and 8 | 194 | |||
| PubMed (N = 136) | #12 | Add | Search (#1 and #6 and #10) Filters: Humans | 136 |
| #11 | Add | Search (#1 and #6 and #10) | 156 | |
| #10 | Add | Search (#8 or #9) | 47,643 | |
| #9 | Add | Search adenoid * | 17,210 | |
| #8 | Add | Search tonsil * | 36,293 | |
| #6 | Add | Search (#2 or #3 or #5) | 504,872 | |
| #5 | Add | Search orthodon * | 73,679 | |
| #3 | Add | Search extraction | 274,317 | |
| #2 | Add | Search expansion | 166,756 | |
| #1 | Add | Search apnea | 58,662 | |
| Cochrane (N = 38) | ID | Search | Hits | |
| #1 | apnea | 9046 | ||
| #2 | Expansion | 5534 | ||
| #3 | Extraction | 21,029 | ||
| #4 | Orthodon * | 4587 | ||
| #5 | #2 or #3 or #4 | 29,693 | ||
| #6 | Tonsil * | 3659 | ||
| #7 | Adenoid * | 1189 | ||
| #8 | #6 or #7 | 4129 | ||
| #9 | #1 and #5 and #8 | 38 | ||
| LILACS (N = 8) | Apnea, orthodon *, extraction, expansion, tonsil *, adenoid * | |||
Study characteristics.
| Year—Principal Author | Type of Study | Type of Treatment | Type of Screening | Sample Size | Age of Participants (Year) Mean + SD | Sex | BMI (kg/m2) Mean + SD |
|---|---|---|---|---|---|---|---|
|
| Case report | RME followed by AT | HST | 2 | 9 | F | / |
|
| Case report | AT followed by twin block | PSG | 1 | 12 | M | 22.2 |
|
| Case report | AT followed by Bionator | PSG | 1 | 3 | F | / |
|
| Case report | At the same time: RME + epiglottoplasty + reduction of the tongue base | PSG | 1 | 8 | F | / |
|
| NRCT | Group 1: AT: 25 | PSG | 52 | Group 1: 3.7 ± 0.92 * | Group 1 and 2: 34M/13F | Group 1: 15.75 ± 1.82 * |
|
| Case report | AT followed by RME | PSG | 1 | 11 | M | 22.4 |
|
| Case—Control | AT followed by RME, | PSG | 24 †: | I: 5.5 ± 1.2 | 14M/10F | / |
|
| Case—Control | Follow-up study of OSA in teenagers after AT + RME treated in their childhood | PSG | 29 | I: 7.6 ± 1.7 | 20M/9F | NR: 15.9 ± 1.9 |
|
| NRCT | Group 1: RME: 40 | HST | Group 1 and 2: 80 | 7.3 | 43M/37F | <24 |
|
| RCT | Group 1: AT followed by RME, | PSG | 31: Group 1: 16 | 6.5 ± 0.2 | 14M/17F | / |
RCT—randomized controlled trial; NRCT—non-randomized controlled trial; OSA—obstructive sleep apnea; AT—adenotonsillectomy; RME—rapid maxillary expansion; MT—myofunctional therapy; WMT—without myofunctional therapy; PSG—polysomnography; HST—home sleep study; I—before treatment; F—final treatment; FU—follow-up; R—patients with relapse; NR—patients without relapse; M—male; F—female; * p < 0.05; † One patient did not have AT.
Quality index.
| 2014 Villa et al. [ | 2013 Guilleminault et al. [ | 2013 Guilleminault et al. [ | 2012 Pirelli al. [ | 2011 Guilleminault et al. [ | ||
|---|---|---|---|---|---|---|
|
| 0 no, 1 yes | 1 | 1 | 1 | 1 | 0 |
|
| 0 no, 1 yes | 1 | 1 | 1 | 1 | 1 |
|
| 0 no, 1 yes | 1 | 1 | 1 | 1 | 1 |
|
| 0 no, 1 yes | 1 | 1 | 1 | 1 | 1 |
|
| 0 no, 1 partially, 2 yes | 1 | 0 | 2 | 0 | 1 |
|
| 0 no, 1 yes | 1 | 1 | 1 | 0 | 1 |
|
| 0 no, 1 yes | 0 | 1 | 1 | 0 | 1 |
|
| 0 no, 1 yes | 0 | 0 | 0 | 0 | 0 |
|
| 0 no, 1 yes | 1 | 1 | 1 | 0 | 1 |
|
| 0 no, 1 yes | 1 | 1 | 0 | 0 | 1 |
|
| 0 no, 1 yes | 0 | 1 | 1 | 1 | 1 |
|
| 0 no, 1 yes | 0 | 0 | 1 | 1 | 1 |
|
| 0 no, 1 yes | 0 | 1 | 1 | 1 | 1 |
|
| 0 no, 1 yes | 0 | 0 | 0 | 0 | 0 |
|
| 0 no, 1 yes | 0 | 0 | 0 | 0 | 0 |
|
| 0 no, 1 yes | 0 | 1 | 1 | 1 | 1 |
|
| 0 no, 1 yes | 1 | 1 | 1 | 1 | 1 |
|
| 0 no, 1 yes | 1 | 1 | 1 | 1 | 1 |
|
| 0 no, 1 yes | 1 | 0 | 1 | 1 | 0 |
|
| 0 no, 1 yes | 1 | 1 | 1 | 0 | 1 |
|
| 0 no, 1 yes | 0 | 0 | 0 | 1 | 1 |
|
| 0 no, 1 yes | 1 | 0 | 1 | 1 | 1 |
|
| 0 no, 1 yes | 0 | 0 | 0 | 0 | 1 |
|
| 0 no, 1 yes | 0 | 0 | 0 | 0 | 0 |
|
| 0 no, 1 yes | 0 | 0 | 1 | 0 | 1 |
|
| 0 no, 1 yes | 1 | 1 | 1 | 0 | 1 |
|
| 0, 1, 2, 3, 4, 5 | 0 | 0 | 0 | 0 | 0 |
|
| 14 | 15 | 20 | 13 | 20 | |
|
| Poor | Fair | Good | Poor | Good | |
Good = 2, Fair = 1, Poor = 2.
CAse REport (CARE) checklist.
| Topic | Item | 2014 Kim et al. [ | 2019 Alexander et al. [ | 2019 Bignotti et al. [ | 2019 Nauert et al. [ | 2018 Gracco et al. [ |
|---|---|---|---|---|---|---|
|
| 1 | 0 | 0 | 1 | 1 | 1 |
|
| 2 | 0 | 0 | 0 | 0 | 0 |
|
| 3a | 0 | 1 | 0 | 0 | 1 |
| 3b | 0 | 1 | 1 | 1 | 1 | |
| 3c | 1 | 1 | 1 | 1 | 1 | |
| 3d | 1 | 1 | 1 | 1 | 1 | |
|
| 4 | 0 | 0 | 0 | 0 | 1 |
|
| 5a | 1 | 1 | 1 | 1 | 1 |
| 5b | 1 | 1 | 1 | 1 | 1 | |
| 5c | 1 | 1 | 1 | 1 | 1 | |
| 5d | 1 | 0 | 1 | 1 | 1 | |
|
| 6 | 1 | 1 | 1 | 1 | 1 |
|
| 7 | 1 | 1 | 1 | 1 | 1 |
|
| 8a | 1 | 1 | 1 | 1 | 1 |
| 8b | 0 | 0 | 0 | 0 | 0 | |
| 8c | 0 | 0 | 0 | 0 | 1 | |
| 8d | 0 | 0 | 0 | 0 | 0 | |
|
| 9a | 1 | 1 | 1 | 1 | 1 |
| 9b | 1 | 1 | 1 | 1 | 1 | |
| 9c | 1 | 1 | 1 | 1 | 1 | |
|
| 10a | 1 | 1 | 1 | 1 | 1 |
| 10b | 1 | 1 | 1 | 0 | 1 | |
| 10c | 0 | 0 | 1 | 1 | 1 | |
| 10d | 0 | 0 | 0 | 0 | 0 | |
|
| 11a | 1 | 1 | 0 | 0 | 0 |
| 11b | 1 | 1 | 1 | 0 | 1 | |
| 11c | 1 | 1 | 1 | 0 | 1 | |
| 11d | 1 | 1 | 1 | 0 | 1 | |
|
| 12 | 0 | 0 | 0 | 0 | 0 |
|
| 13 | 0 | 0 | 0 | 0 | 0 |
|
| 18 | 19 | 20 | 16 | 23 |
Yes = 1, No = 0.
Summary of severity of OSA.
| Year—Principal Author | Type of Treatment | AHI Initial (Events/h) | AHI Intermediate (Events/h) Mean + SD | AHI Final (Events/h) | RDI Initial (Events/h) | RDI Intermediate (Events/h) | RDI Final (Events/h) Mean + SD |
|---|---|---|---|---|---|---|---|
|
| RME followed by AT | Patient A: 74 | Post RME: | Patient A: 0.9 | / | / | / |
|
| AT followed by twin block | 25.5 | Post AT: 3.4 | 0.7 | / | / | / |
|
| AT followed by Bionator | / | Post AT: 10.2 | 5-year follow-up: normal cognitive development and any evidence of OSA | / | / | / |
|
| At the same time: RME + epiglottoplasty + reduction of the tongue base | 21.8 | / | 0.6 | / | / | / |
|
| Group 1: AT: 25 | Group 1: 17.25 ± 13.94 * | / | Group 1: 1.79 ± 1.82 * | / | / | / |
|
| AT followed by RME | / | 18.9 | F: 4.4 | / | 19.8 | F and FU: 5.9 |
|
| AT followed by RME, | 10.5 ± 2.6 | Post AT†: 4.3 ± 1.6 | F: 0.4 ± 0.3 | / | / | / |
|
| Follow-up study of OSA in teenagers after AT + RME treated in their childhood | 9 ± 5 | Post AT: 3 ± 4 | F: 0.4 ± 0.4 | 15 ± 6.4 | Post AT: 7 ± 6 | F: 0.6 ± 0.5 |
|
| Group 1: RME: 40; | Group 1 and 2: 12.8 | Group 3: | Group 1 (6/40) and G2 (15/40): 6.5 ±3.1 | / | / | / |
|
| Group 1: AT followed by RME, | Group 1: 12.5 ± 0.8 | Group 1: 4.9 ± 0.6 | Group 1: 0.9 ± 0.3 | Group 1: 21.3 ± 1.0 | Group 1: 8.0 ± 0.7 | Group 1: 1.6 ± 0.6 |
OSA—obstructive sleep apnea; AT—adenotonsillectomy; RME—rapid maxillary expansion; MT—myofunctional therapy; WMT—without myofunctional therapy; F—final treatment; FU—follow-up; R—patients with relapse; NR—patients without relapse; * p < 0.05; † One patient did not have AT.
Summary of oxygen saturation.
| Year—Principal Author | Lowest SaO2 Initial (%) Mean + SD | Lowest SaO2 Intermediate (%) Mean + SD | Lowest SaO2 Final (%) Mean + SD | Average Sa02 Initial (%) Mean + SD | Average SaO2 Intermediate (%) Mean + SD | Average SaO2 Final (%) Mean + SD | ODI Initial (Events/Hour) | ODI Intermediate (Events/h) | ODI Final (Events/h) |
|---|---|---|---|---|---|---|---|---|---|
|
| / | / | / | / | / | / | / | / | / |
|
| Nadir: 89 | Nadir: 93 | Nadir: 50 | 97.3 | 96.0 | 96.0 | 22.0 | 0.7 | 3.2 |
|
| / | / | / | / | / | / | / | / | / |
|
| / | / | / | 96.5% | / | 98.1 | 23.4 | / | 1 |
|
| / | / | / | Group 1: | / | Group 1: | / | / | / |
|
| / | Nadir: 60 | Nadir FT: 85 | / | / | / | / | / | / |
|
| 90 ±1.5 | Post AT†: 92 ± 1 | F: 95 ± 1 | / | / | / | / | / | / |
|
| 91 ± 2.5 | Post AT: 94 ± 3 | F: 98 ± 1.5 | / | / | / | / | / | / |
|
| / | / | / | / | / | / | / | / | / |
|
| Group 1: | Group 1: 95.2 ± 0.3 | Group 1: | / | / | / | / | / | / |
AT—adenotonsillectomy; MT—myofunctional therapy; WMT—without myofunctional therapy; F—final treatment; FU—follow-up; R—patients with relapse; NR—patients without relapse; SaO2—oxygen saturation; ODI—oxygen desaturation index; * p < 0.05; † One patient did not have AT.
Figure 1Flow chart of selection process.